Interactions of arene ruthenium metallaprisms with human proteins by Paul, Lydia E. H. et al.
Organic &
Biomolecular Chemistry
PAPER
Cite this: Org. Biomol. Chem., 2015,
13, 946
Received 15th October 2014,
Accepted 12th November 2014
DOI: 10.1039/c4ob02194k
www.rsc.org/obc
Interactions of arene ruthenium metallaprisms
with human proteins†
Lydia E. H. Paul,a Bruno Therrien*b and Julien Furrer*a
Interactions between three hexacationic arene ruthenium metallaprisms, [(p-cymene)6Ru6(tpt)2-
(dhnq)3]
6+, [(p-cymene)6Ru6(tpt)2(dhbq)3]
6+ and [(p-cymene)6Ru6(tpt)2(oxa)3]
6+, and a series of human
proteins including human serum albumin, transferrin, cytochrome c, myoglobin and ubiquitin have been
studied using NMR spectroscopy, mass spectrometry and circular dichroism spectroscopy. All data
suggest that no covalent adducts are formed between the proteins and the metallaprisms. Indeed, in
most cases electrostatic interactions, leading to precipitation of protein-metallaprism aggregates, have
been observed. In addition, with the smallest proteins, ubiquitin, myoglobin and cytochrome c, the pres-
ence of the hexacationic arene ruthenium metallaprisms induces structural changes of the proteins, as
emphasized by circular dichroism. The results suggest that proteins are certainly a biological target for
these metalla-assemblies.
Introduction
Since the fortuitous discovery of the chemotherapeutic pro-
perties of platinum complexes by Rosenberg in the 1960s,1 a
lot of eﬀort has been devoted to identify cellular targets and
mechanisms of action of metal-based drugs. Initially, DNA was
thought to be the primary and most eﬀective target. Conse-
quently most of the research was focused on improving the
DNA binding properties of metal-based drugs. This approach
resulted in rather unselective compounds that often exhibit
significant side eﬀects.2 It is now well accepted that one
should not focus on DNA when developing new metal-based
drugs. Indeed, current research aims at developing new com-
pounds with new biological targets. This quest for finding
truly selective compounds has resulted in what is today known
as targeted therapy.3,4 The increased selectivity represents the
most important feature of the newly developed drugs in order
to minimize side eﬀects and to prevent the development of
resistance mechanisms.5,6
As emphasized in the literature, in order to successfully
design and develop new and selective metal-based drugs, it is
of the highest importance to understand the mode of action of
established and also of newly developed anticancer drugs.7,8
Among the new generation of metal-based drugs, ruthenium
derivatives appear to be quite promising. These complexes
selectively bind to proteins or inhibit enzymes known to be
overexpressed in many types of cancer.7,9–13 To date, much
work has been done to elucidate the mode of action of various
ruthenium-based drug candidates,14,15 but the way they exert
their antitumoural or antimetastatic eﬀects is not yet fully
understood, even for NAMI-A and NKP-1339, which have suc-
cessfully completed clinical trials.14,16–18 By analogy with plati-
num complexes, it was originally assumed that DNA binding
was the main reason for the anticancer activity of ruthenium
complexes.16,19–21 While the ability of ruthenium complexes to
bind to DNA has been demonstrated,22–25 in particular for
arene ruthenium ethylenediamine complexes,26,27 it was also
observed that DNA binding of ruthenium was weaker and
diﬀerent from that observed for platinum complexes.22 Recent
examples of rationally designed metal complexes that inhibit
enzymatic activities involved in cancer proliferation were inves-
tigated,28,29 including ruthenium half-sandwich complexes
that bind to specific enzymes.30,31 Dyson and co-workers have
shown that several complexes of the RAPTA family bind rather
selectively to Cathespin B,9 a prognostic marker for various
types of cancer.32 The interactions between metal-based drugs
and enzymes or proteins have to be expected since proteins are
ubiquitous in every tissue and in the blood stream of the
human body and any potential anticancer drug will be facing
various proteins either in the blood or in the cytosol on their
way to cancer cells.
Our previous work describing the reactivity of the metal-
laprisms [(p-cymene)6Ru6(tpt)2(dhnq)3]
6+ ([1]6+; tpt = 2,4,6-tris-
(pyridyl-4-yl)-1,3,5-triazine; dhnq = 5,8-dihydroxy-1,4-naphtho-
quinonato), [(p-cymene)6Ru6(tpt)2(dhbq)3]
6+ ([2]6+; dhbq = 2,5-
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dihydroxy-1,4-benzoquinonato) and [(p-cymene)6Ru6-
(tpt)2(oxa)3]
6+ ([3]6+; oxa = oxalato) (Fig. 1) towards free amino
acids suggests an increasing reactivity from [1]6+ to [3]6+, with
in some cases the formation of degradation products,
especially in the presence of basic amino acids (Arg, His and
Lys).33–35 For this reason, interactions can be expected with
proteins, especially with ubiquitin. This small protein pos-
sesses a C-terminal tail and seven lysine residues which are
potentially accessible for the metallaprisms.
Herein we report the NMR, CD and MS study of the inter-
actions between the hexanuclear metallaprisms [1]6+–[3]6+,
with two serum proteins, human serum albumin (HsA) and
transferrin (Tf), and three cytosolic proteins, cytochrome
c (Cyt c), myoglobin (Mb) and ubiquitin (Ub). All proteins are
water-soluble and stable in solution under physiological con-
ditions. Moreover, high-resolution crystal structures or NMR
structural data are available, making them ideal candidates for
such an investigation.36–40
Albumin, known to transport numerous important bio-
molecules and drugs in the cytoplasm,41 and transferrin,
which controls the level of free iron in biological fluids, may
react immediately with the metallaprisms, if they are admini-
strated intravenously. Cytosolic proteins also possess impor-
tant functions: cytochrome c is involved in apoptotic
pathways,42 while ubiquitin is relevant in posttranslational
modifications together with the proteasome system,43 and
myoglobin is the primary oxygen-carrying pigment of muscle
tissues.44
Results and discussion
NMR and MS investigations of the interaction between
metallaprisms and proteins
Interactions between the proteins and the metallaprisms were
first monitored in aqueous solution at 37 °C by 1H NMR spec-
troscopy over a time frame of 96 h. As an example, Fig. 2 shows
the 1H NMR spectra obtained after mixing HsA and [1]6+. Over
time, the intensity of the protein’s resonances and of the tpt
and dhnq ligands of the metallaprism decreased considerably.
The 1H NMR spectra suggest that the metallaprism [1]6+
induces the precipitation of HsA without formation of a
covalent bond between the metallaprism and HsA. Accord-
ingly, in the NMR tube a precipitate was visible. Similar to
[1]6+, precipitation of the proteins were observed for the mix-
tures [2]6+/HsA and [3]6+/HsA (Fig. S1 and S2†).
For the mixtures metallaprism/Cyt c and metallaprism/Tf
(Fig. S3–S5 and Fig. S6–S8†), the 1H NMR spectra indicate that
Fig. 2 1H NMR spectra of the mixture HsA/[1]6+ (molar ratio 1 : 10)
recorded in D2O at 37 °C between 0 h and 96 h. The
1H NMR spectrum
of free HsA is shown at the bottom as reference. The p-cymene reson-
ances of the metallaprism are labelled by (■).
Fig. 1 Structures of the hexacationic metallaprisms [1]6+, [2]6+ and [3]6+.
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metallaprisms [1]6+ and [3]6+ as well as the proteins precipitate,
as visible in the respective NMR tubes. However, for metallapr-
ism [2]6+ the intensity of the signals associated to the metal-
laprism remains relatively strong over the 96 hours period,
suggesting a slower interaction between [2]6+ and the two pro-
teins (Fig. S4 and S7†).
In the case of Mb, a diﬀerent behaviour was observed for
the three metallaprisms. In the presence of [1]6+, minimal pre-
cipitation of Mb was observed (Fig. S9†), the intensity of the
protein signals remaining strong after 96 h. However, the reso-
nance’s intensity of the metallaprism [1]6+ dropped rapidly,
and the resonances were overlapped with those of the protein
after only 24 hours. A similar observation was made with
metallaprism [2]6+ but at a much slower rate (Fig. S10†).
Additionally, the resonances of the protein became gradually
broadened, indicating an ongoing reaction or an interaction
with the metallaprism [2]6+. On the other hand, in the pres-
ence of [3]6+, Mb precipitated almost completely while the
signals of the metallaprism remained sharp and well resolved
(Fig. S11†).
For ubiquitin, the 1H NMR spectra (Fig. 3, and Fig. S12 and
S13†) revealed that Ub remained unaﬀected upon addition of
the metallaprisms and did not precipitate in any case. This
outcome is rather surprising because Ub possesses a C-term-
inal tail and several lysine residues potentially accessible for
the metallaprisms. Ub was therefore anticipated to react with
the metallaprisms, since it was previously shown that metal-
laprisms rapidly react with lysine.33–35 The only changes
observed in the NMR spectra can be ascribed to the disappear-
ance of the signals associated to the metallaprism [1]6+, and to
a lesser extent to a reduction of the intensity of the signals of
metallaprisms [2]6+. However, for metallaprism [3]6+,
additional signals in the aromatic region of the p-cymene
protons (5–6 ppm) are observed, together with the signals of
the p-cymene ligands of the intact metallaprism. These new
signals can either be tentatively ascribed to decomposition
products or to protein-metallaprism adducts.
In order to determine the nature of the interaction between
the proteins and the metallaprisms, MALDI-TOF mass spectra
were recorded in the negative mode. The MALDI-TOF spectra
of the free proteins are given in Fig. S14–S18.† We were
however unable to get exploitable spectra from the mixtures
metallaprism/protein owing to the rapid precipitation of the
proteins. In a second attempt, the precipitates were collected,
dried and dissolved in DMSO, and MALDI-TOF MS measure-
ments were repeated, but remained silent. The ESI mass
spectra of the precipitates were also recorded in the positive
mode, giving unusable spectra as well (data not shown).
Although not conclusive, the ESI mass spectra support the
results obtained by NMR spectroscopy, which suggest that no
covalent bonds between the metallaprisms and the proteins
are formed. Indeed, upon breakage of the metallaprisms, the
ESI mass spectra would have exhibited peaks corresponding to
complexes similar to those previously reported in the litera-
ture, such as [(p-cymene)Ru-Cyt c + 5H+]8+,45 [(p-cymene)Ru-
Ub]+ and [2{Ru(p-cymene)}-Ub]+.46 Interestingly, the results
found for these three metallaprisms are in contrast to those
observed with other ruthenium complexes. For instance,
KP1019 was shown to bind to apoTf as evidenced by ESI-mass
and CD spectra,47 and RAPTA-C was shown to bind to Ub and
metallothionein-2.48
All NMR and MS experiments strongly suggest that no
covalent binding takes place between the metallaprisms and
the five selected proteins. It is more plausible that electrostatic
interactions between the proteins and the metallaprisms cause
the observed precipitation: A phenomenon commonly
observed for proteins interacting with cations.49,50
CD investigation of the interaction between the metallaprisms
and proteins
Circular dichroism (CD) is an important tool for studying the
structural changes of proteins in solution.51,52 Fig. 4 shows the
CD spectra of the proteins alone in comparison with the
spectra measured after addition of the metallaprisms (1 : 10
ratio). In the case of HsA, upon addition of the metallaprisms
the spectra exhibited a strong decrease in the intensity of the
negative bands. This reduced intensity can be easily under-
stood, knowing that HsA precipitates in solution in the pres-
ence of the metallaprisms, as observed by NMR. According to
the CD spectra shown in Fig. 4, it can be assumed that the
original α-helical structure of HsA is retained upon addition of
Fig. 3 1H NMR spectra of the mixture Ub/[1]6+ (molar ratio 1 : 10, D2O,
37 °C) recorded between 0 h and 96 h. The 1H NMR spectrum of free
ubiquitin is shown as reference at the bottom. The p-cymene reson-
ances of the metallaprism are labelled by (■).
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metallaprisms [2]6+ and [3]6+. With metallaprism [1]6+, on the
other hand, an additional increase of the positive band was
observed, suggesting a small alteration of the protein folding.
Although the overall α-helical structure of HsA remains, the
positive band could suggest the refolding at least in part of the
protein into a β-sheet like structure, as previously noted.51,53
The data suggests that electrostatic interactions take place
between the metallaprisms and HsA which lead to protein pre-
cipitation but not to the formation of covalent bonds. It seems
also that HsA undergoes minimal conformational changes
upon addition of metallaprism [1]6+.
Similar to HsA, the intensity of the CD band associated to
Tf decreased upon addition of the metallaprisms. Unlike HsA,
the intensity reduction was less pronounced, but a significant
decrease could be observed with metallaprism [2]6+ compared
to metallaprisms [1]6+ and [3]6+. These observations are con-
sistent with the NMR data, in which the precipitation of Tf was
more noticeable with metallaprism [2]6+. In solution, the Tf
protein exhibits a random coil-like structure51 which does not
change upon addition of the metallaprisms.
For Cyt c and Mb, the CD spectra also exhibited a strong
decrease of the band intensity upon addition of the metallapr-
isms. With metallaprism [2]6+, the CD signal disappeared com-
pletely in both cases while in the presence of the other two
metallaprisms, an additional change in the structure of the
CD band was observed. In the case of [2]6+, the complete van-
ishing of the CD band cannot be exclusively attributed to the
precipitation of the proteins. It is more plausible that soluble
protein aggregates are formed in solution due to an interaction
with the cationic metallaprisms. The aggregates would no
longer be chiral and therefore show no bands in the CD spec-
trum.54 Both Cyt c and Mb possess a slight α-helical struc-
Fig. 4 CD spectra of the mixtures containing the proteins and the metallaprisms (molar ratio 1 : 10). Left column: top = HsA, middle = Cyt c,
bottom = Mb; right column: top = Tf, bottom = Ub.
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ture51,55 in solution, but after 48 h in the presence of [1]6+ and
[3]6+ the CD signals represent a protein folded in a random
coil structure.51 This change in the protein folding can be ten-
tatively attributed to a change in the secondary structure of the
proteins, caused by electrostatic interactions between Cyt c or
Mb and the metallaprisms [1]6+ and [3]6+.
Ubiquitin was assumed to be the most likely protein to
react with the metallaprisms, due to the presence of an
unstructured C-terminal tail and accessible Lys residues. Sur-
prisingly, neither the mass spectra nor the NMR spectra have
indicated covalent interactions between Ub and the metallapr-
isms. On the other hand, the CD spectra suggest that strong
electrostatic interactions take place with the metallaprisms
[2]6+ and [3]6+, the CD band being significantly quenched.
Moreover, in the presence of [1]6+, the negative band of Ub was
shifted, while the intensity of the band remained strong
(Fig. 4). As shown by NMR spectroscopy, these significant
changes in the CD spectrum of Ub cannot be attributed to the
precipitation of the protein. A more plausible explanation for
the disappearance could be the formation of soluble Ub aggre-
gates in solution, due to the interaction with the cationic
metallaprisms [2]6+ and [3]6+ as described for Cyt c and Mb.
Unlike [2]6+ and [3]6+, the intensity of the CD band is almost
completely retained but the nature of the band is altered in
the presence of metallaprism [1]6+. From the original two nega-
tive bands only one remains visible in the spectrum and
suggests that the protein adopts a random coil-like struc-
ture,51,54 due to electrostatic interactions with [1]6+.
The results collected from the NMR, MS and CD experi-
ments have revealed the occurrence of electrostatic inter-
actions between the proteins and the metallaprisms: the
outcomes ranging from precipitations to structural changes of
the proteins. In order to get further insight into these protein-
metallaprism electrostatic interactions, we modelled the elec-
trostatic surface potentials for the selected proteins (Fig. 5 and
Fig. S19–S21†). The ratios of negative and positive surface
potentials determined by optical inspection are summarized
in Table 1, together with other parametrical data. HsA pos-
sesses a high amount of negatively charged surface areas
(Fig. S19†) and can thereby strongly interact with the positively
charged metallaprisms ([1]6+–[3]6+). These electrostatic inter-
actions most probably lead to the observed precipitation of the
protein and of the metallaprisms. Similar arguments can
explain the behaviour of Tf (Fig. 5) and Mb (Fig. S20†). Both
proteins possess negatively charged areas on the surface which
are readily available for interactions with the metallaprisms.
Fig. 5 Electrostatic potentials on the protein surface (top: transferrin, bottom: ubiquitin) modelled with PyMOL (v 1.7.2.1) (left). The sequence was
modelled from the RSCB pdb ﬁles (3QYT for Tf38 and 1UBQ for Ub40). Areas of negative potentials are shown in red, areas of positive potentials in
blue and areas of neutral potentials in white. The structure of the protein created from the same pdb ﬁles is shown in the middle. The structure of
metallaprism [2]6+ (right) was added to highlight the size diﬀerence between the two entities.
Paper Organic & Biomolecular Chemistry
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The strong eﬀect observed in the CD spectra of Mb could be a
result of the spatial distribution of the charged areas. The posi-
tive and the negative charges are mainly found on opposite
hemispheres of the protein and upon interaction with the
highly positively charged metallaprisms a refolding of the
protein seems likely, thus minimizing electrostatic repulsion
between the positive charges (Fig. S20†). The same explanation
could also be applied to the strong structural changes observed
for Ub (Fig. 5) and Cyt c (Fig. S21†). The charges are again loca-
lized mostly on opposite sides of the protein surface and an
interaction between the negative charged area and the metal-
laprisms should lead to refolding of the protein and even
aggregation which can result in the disappearance of the CD
signals (Fig. 4). In addition, negatively and positively charged
surface fractions are observed in close proximity for Cyt c. This
could lead to both electrostatic attraction and repulsion upon
contact with the positively charged metallaprisms. The disap-
pearance of the CD and NMR signals could therefore also be
attributed to the precipitation of the protein due to electro-
static interactions.
Considering our results, it is unlikely that the metallapr-
isms [1]6+–[3]6+ bind covalently to proteins. They rather
strongly reduce their solubility and lead to the precipitation of
the proteins. Proteins often show this behaviour in solution
with cations present.49,50,57 Also, the electrostatic interactions
cause structural alterations in the proteins’ secondary struc-
ture as the CD spectra of Mb, Cyt c and Ub indicate severe
spectral changes in solution upon addition of the
metallaprisms.
Conclusions
The interaction of three hexacationic arene ruthenium metal-
laprisms with several proteins has been monitored by MS spec-
trometry, NMR and CD spectroscopies. Electrostatic
interactions between the metallaprisms and the proteins,
human serum albumin (HsA), transferrin (Tf), myoglobin
(Mb), cytochrome c (Cyt c) and ubiquitin (Ub), were observed.
In general, with the exception of ubiquitin, the NMR spectra
show precipitations of the proteins in D2O. Electrostatic inter-
actions that induce the precipitation of the proteins seem to
be the foremost mode of interaction. The CD spectra support
these findings, with additional information regarding the
experiments for which no precipitation of the proteins was
observed. In these particular cases, the metallaprisms induce
quite severe changes to the secondary structure of the proteins.
For HsA and Tf the observed reduction of the band intensity
was attributed to protein precipitation, while for the other
three proteins Cyt c, Mb and Ub, the spectral changes were
ascribed to structural alterations. These changes seem to be
induced by the electrostatic interactions between negatively
charged areas on the protein surface and the metallaprisms.
Overall, these results suggest that proteins are certainly bio-
logical targets for these arene ruthenium metallaprisms. The
supramolecular interaction between the hexacationic metalla-
assembly and proteins appears to be electrostatic in nature,
and this strong interaction in water induces precipitation or
unfolding of the proteins, which might in part explain the bio-
logical activity of these metallaprisms.
Experimental
General remarks
Chemicals obtained from commercial suppliers were of
analytical grade and used as received. The proteins human
serum albumin, transferrin, myoglobin, ubiquitin and cyto-
chrome c were obtained from Sigma Aldrich. The arene ruthe-
nium metallaprisms [1](CF3SO3)6, [2](CF3SO3)6 and [3](CF3SO3)6
were synthesised according to published methods.58–60
NMR spectroscopy
If not otherwise stated, all experiments were carried out by
mixing the metallaprisms [1](CF3SO3)6–[3](CF3SO3)6 in
0.05 mL D2O with 0.1 equivalent of the proteins. All reactions
were monitored by 1D 1H NMR spectroscopy over a time
period of up to 96 h. All experiments were undertaken at pD =
7, i.e. close to the pH value of the bloodstream. The pD values
of D2O solutions were measured by using a glass electrode and
addition of 0.4 to the pH meter reading.61,62 To mimic physio-
logical conditions as closely as possible during the experi-
ments, oxygen was not excluded from solutions.
NMR data were acquired at a temperature of 37 °C using a
Bruker AvanceII 500 MHz NMR spectrometer, equipped with
an inverse 1.7 mm triple channel (1H, 31P, 13C) z-gradient
Table 1 Selected parametrical data for Tf, HsA, Mb, Cyt c and Ub
Protein Molecular weighta Rmin
b Overall charge1 Domainsc
Relative positively/negatively
charged surfaced
Tf 75.1 kDa 2.78 nm 0.4 2 +/−
HsA 66.4 kDa 2.67 nm −12.2 3 −
Mb 16.9 kDa 1.69 nm 2.6 1 −
Cyt c 11.7 kDa 1.50 nm 9.6 1 +
Ub 8.6 kDa 1.35 nm 0.2 1 −
a Calculated with http://protcalc.sourceforge.net, sequences taken from pdb files (HsA = 1UOR, Cyt c = 1HRC, Tf = 3QYT, Mb = 4DC8, Ub = 2ZCC).
b Calculation based on ref. 56, Rmin = minimal radius of sphere that could contain a given mass of protein.
c Taken from http://www.uniprot.org,
(UniProtKB: HsA = P02768, Cyt c = P00004, Tf = P02787, Mb = P6808, Ub = P0CH28). d Estimated from model structures shown in Fig. 5, S19–S21.
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microprobehead. All 1D 1H NMR data were measured with 1 k
transients into 64 k data points over a width of 25 ppm using a
classical presaturation to eliminate the water resonance.
A relaxation delay of 2 s was applied between transients.
Mass spectrometry studies
MALDI-TOF mass spectrometry analyses were performed on a
Bruker Daltonics Autoflex III MALDI-TOF mass spectrometer
equipped with a smartbeam Nd:YAG-laser (355 nm) providing
a repetition rate of 200 Hz.
The three metallaprisms, using each time 1 mg of the
corresponding triflate salts ([1](CF3SO3)6–[3](CF3SO3)6) in 1 mL
H2O, were incubated with the selected protein at a 10 : 1 molar
ratio for 48 h at 37 °C. Then, all samples were analysed
using various matrices depending on the protein. For HsA, Tf,
Cyt c and Ub, CHCA (α-cyano-4-hydroxycinnamic acid) was
applied and for Mb a SA (sinapic acid) matrix was used. The
Xcalibur software package (Xcalibur 2.0.7, Thermo Fisher
Scientific) was used for instrument control and data
processing.
Circular dichroism studies
The circular dichroism (CD) spectra of the proteins in the pres-
ence or absence of the metallaprisms were accumulated on a
J-715 Jasco Spectropolarimeter (with Xe lamp, purged with
nitrogen). All experiments were measured using a Hellma
Suprasil R 100-QS 0.1 cm cuvette. The metallaprisms
[1](CF3SO3)6–[3](CF3SO3)6 and the proteins were dissolved in
H2O and incubated for 48 h before data collection. For each
sample, the mixture was scanned three times using a rate of
50 nm min−1 at 20 °C. The range of measurement was
190–700 nm, pitch was 0.5 nm, response 16 s and band
1.0 nm. The nitrogen flow was kept around 5 L min−1. All
spectra were corrected for solvent signal contribution and
measured under identical conditions.
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